Literature DB >> 14752817

Non-HFE hemochromatosis.

Antonello Pietrangelo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14752817     DOI： 10.1002/hep.20007

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  20 in total

1.  Identification of ferroportin disease in the Indian subcontinent.

Authors:  D F Wallace; P Browett; P Wong; H Kua; R Ameratunga; V N Subramaniam
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

2.  Down-regulation of hepcidin in porphyria cutanea tarda.

Authors:  Richard S Ajioka; John D Phillips; Robert B Weiss; Diane M Dunn; Maria W Smit; Sean C Proll; Michael G Katze; James P Kushner
Journal:  Blood       Date:  2008-09-22       Impact factor: 22.113

3.  First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin.

Authors:  D F Wallace; L Summerville; P E Lusby; V N Subramaniam
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

Review 4.  Screening in liver disease.

Authors:  Paolo Del Poggio; Marzio Mazzoleni
Journal:  World J Gastroenterol       Date:  2006-09-07       Impact factor: 5.742

5.  Transferrin receptor 2 protein is not expressed in normal erythroid cells.

Authors:  Alessia Calzolari; Silvia Deaglio; Nadia Maria Sposi; Eleonora Petrucci; Ornella Morsilli; Marco Gabbianelli; Fabio Malavasi; Cesare Peschle; Ugo Testa
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

6.  Ferroportin and erythroid cells: an update.

Authors:  Luciano Cianetti; Marco Gabbianelli; Nadia Maria Sposi
Journal:  Adv Hematol       Date:  2010-08-11

7.  A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis.

Authors:  Marie-Laure Island; Anne-Marie Jouanolle; Annick Mosser; Yves Deugnier; Véronique David; Pierre Brissot; Olivier Loréal
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

8.  TIMP3 deficiency exacerbates iron overload-mediated cardiomyopathy and liver disease.

Authors:  Pavel Zhabyeyev; Subhash K Das; Ratnadeep Basu; Mengcheng Shen; Vaibhav B Patel; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-01-26       Impact factor: 4.733

9.  Structure of the membrane proximal oxidoreductase domain of human Steap3, the dominant ferrireductase of the erythroid transferrin cycle.

Authors:  Anoop K Sendamarai; Robert S Ohgami; Mark D Fleming; C Martin Lawrence
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-21       Impact factor: 11.205

10.  Analysis of HFE and non-HFE gene mutations in Brazilian patients with hemochromatosis.

Authors:  Paulo Lisboa Bittencourt; Maria Lúcia Carnevale Marin; Cláudia Alves Couto; Eduardo Luiz Rachid Cançado; Flair José Carrilho; Anna Carla Goldberg
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.